<DOC>
	<DOCNO>NCT00606164</DOCNO>
	<brief_summary>The main purpose study find safe single dose bryostatin 1 patient Alzheimer 's Disease ( AD ) . This study also do 1 ) determine effective single dose bryostatin 1 treatment AD , 2 ) find happens bryostatin 1 enters body measure level bryostatin 1 blood , 3 ) measure substance blood ( protein kinase C ) may help good understand bryostatin 1 work .</brief_summary>
	<brief_title>Safety , Efficacy , Pharmacokinetics , Pharmacodynamics Study Bryostatin 1 Patients With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>Male female , age 50 yr old . Females must nonchildbearing potential ( surgically sterilize least 2 yrs postmenopausal ) Must cognitive deficit present least 1 yr &amp; meet DSMIVTRTM criterion AD &amp; meet NINCDS/ADRDA criterion presence probable AD Severity AD must mild moderate , document MMSE score 1226 Has CT scan MRI scan within prior 12 month , compatible diagnosis probable AD Ability walk , least assistive device Vision &amp; hear sufficient comply test Normal cognitive &amp; social functioning prior onset dementia Consistent caregiver accompany patient assessment visit Sufficient basic education able complete cognitive assessment Living outside institution Informed consent sign &amp; dated patient legal representative Has provide write authorization use &amp; disclosure protect health information Dementia due condition AD , include vascular dementia ( modify Hachinski Ischemic Scale â‰¥ 5 ; positive NINDSAIREN criterion ) Evidence clinically significant unstable cardiovascular , renal , hepatic , gastrointestinal , neurological , metabolic disease within past 6 month ( determined medical history , ECG result , chest xray , physical examination ) Use drug within 14 day prior randomization unless dose drug &amp; condition treat stable least 30 day &amp; expect remain stable study &amp; neither drug condition treat expect interfere study endpoint Any medical psychiatric condition may require medication surgical treatment study Life expectancy le 6 month Any screen laboratory value outside normal range deem clinically significant investigator Use investigational drug within 30 day prior screen visit entire study Significant neurological disease AD , include cerebral tumor , Huntington 's Disease , Parkinson 's Disease , normal pressure hydrocephalus , &amp; entity Major depression accord DSMIV Psychotic episode require hospitalization antipsychotic therapy 2 week within past 10 yr , link AD Agitation sufficient preclude participation trial Alcohol drug dependence diagnose within past 10 yr Epilepsy antiepileptic drug therapy Abnormal laboratory test might point another etiology dementia : serum B12 , folate , thyroid function , electrolyte , syphilis serology Musculoskeletal disease could interfere assessment Acute poorly control medical illness : blood pressure &gt; 180 mmHg systolic 100 mmHg diastolic ; myocardial infarction within 6 month ; uncompensated congestive heart failure ( NYHA Class III IV ) , severe renal , hepatic gastrointestinal disease could alter drug pharmacokinetics ; blood glucose &gt; 180 mg/dl repeat test entry study need insulin therapy Previous randomization trial participation another investigational trial &lt; 2 month prior randomization Likelihood , accord clinical judgment , transfer nursing home within 6 month Change dosage concomitant antidepressant within 30 day prior randomization Lack caregiver Pregnant lactating female Patients judgment Investigator may unreliable uncooperative evaluation procedure outline protocol HIV positive Hepatitis B C positive Concomitant use medication AD antidepressant medication dose regimen stabilize least 30 day prior enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>bryostatin 1</keyword>
	<keyword>bryostatin</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>protein kinase C</keyword>
</DOC>